Our Mission
Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe and effective technologies that can transform cancer care.
The Galleri test is a first-of-its-kind multi-cancer early detection (MCED) test that can detect a signal shared by more than 50 cancer types and predict the tissue type or organ associated with the signal to help healthcare providers determine next steps.
Multi-cancer early detection (MCED) blood tests analyze DNA that has been shed by all cells, including cancer cells, into the bloodstream, looking for abnormal methylation patterns on those cell-free DNA fragments that may indicate the presence of cancer.
GRAIL’s methylation technology preferentially targets the most informative regions of the genome and uses machine-learning algorithms to detect methylation patterns associated with cancer and when found, to predict the cancer signal origin.
Who We Are
GRAIL is a healthcare company innovating to solve medicine’s most important challenges. Our team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it is more treatable and potentially curable.
;
On the latest episode of #TheCancerSignal podcast, learn how cancer screening was impacted by the COVID-19 pandemic and what that meant for early cancer detection: https://bit.ly/40YYW3F
We’re initiating a real-world study to evaluate the clinical impact of #MCED screening among Medicare beneficiaries.
Learn more here:
Please see enclosed video providing a study overview: https://bit.ly/47FLRhB
GRAIL To Initiate REACH Study To Evaluate Clinical Impact Of Galleri® Multi-Cancer Early Detection…
Prospective, Multi-Center Study Will Assess the Clinical Impact of Galleri® in addition to Currently Recommended Canc…
bit.ly
We are proud to announce that GRAIL has received ISO 13485 Certification, which indicates that GRAIL has implemented robust policies and procedures for the development and manufacture of regulated medical products. https://bit.ly/3R1ADyB
We attended this year’s #ISPOREurope to present two posters on real-world implications of multi-cancer early detection (#MCED). Explore the results: https://bit.ly/3ufa1Bd
At GRAIL, we are guided by our commitment to changing the world. We are honored to be recognized as a top biopharma company on @BioSpace’s 2024 Best Places to Work list. Learn more: https://bit.ly/3TOYVtU
Though Cindy had no symptoms, her husband, Carlos, urged her to take a multi-cancer early detection (#MCED) test. They were shocked when she received a “cancer signal detected” result.
Hear their story: https://bit.ly/44RHQVD
